They would accept a dead vaccine, say many skeptics and hesitant about the Corona vaccination, such as Sahra Wagenknecht. This could soon be the case: the American pharmaceutical company Novavax has applied for a marketing authorization in the EU.
Leif Erik Sander, head of the infection immunology research group at Charité Berlin, would welcome more people deciding to get vaccinated as a result. At the same time, however, he expresses his skepticism as to whether this will actually happen. In his opinion, the perception of protein vaccines as traditional, unlike newer mRNA vaccines, is only partially correct.
Nanoparticles with a new adjuvant
“Of course there are quite a few,” says Sander, considering that the principle of using killed viruses or viral components as a vaccine has been in use for a long time. But, “Research has also been done on mRNAs, if you will, since the 1960s.”
In addition, inactivated vaccines would no longer be produced as before:
“These new protein vaccines are also produced recombinantly using genetic engineering, because they work in a modern, efficient and very precise way. And also the way this new vaccine is formulated by Novavax, for example, there are small nanoparticles with a new type of auxiliary substance, a new type of adjuvant. “
In this regard, he fears that this procedure will again provoke criticism among skeptical vaccinators.
Approval date still unclear
It’s also unclear when the Novovax vaccine will actually hit the market: “Actually, we’ve been waiting for it for a long time, and it’s been delayed again and again. ”
However, it could be so far in January. But then it would be too late to break the fourth wave.
The current wave will likely eclipse anything that has happened before. “You have a very high risk of infection if you are not vaccinated, and there is also a high risk of disease.”
In this context, the immunologist warns that it is very risky to wait for the vaccine to die, especially since the vaccines already approved are “extremely safe” and “very effective”.